Multidisciplinaire richtlijn Cardiovasculair ... - Diliguide

Vrijkotte TGM. Workstress and Cardiovascular Disease Risk (proefschrift). Amsterdam: Vrije
Universiteit, 2001.
Waeber B, Burnier M, Brunner HR. Compliance with antihypertensive therapy. Clin Exp
Hypertens 1999;21:973-85.
Walma EP, Hoes AW, Van Dooren C, Prins A, Van der Does E. Withdrawal of long-term diuretic
medication in elderly patients: a double blind randomised trial. BMJ 1997;315:464-8.
Walma EP, Wiersma Tj. NHG-Standpunt Diagnostiek en behandeling van familiaire
hypercholesterolemie. Huisarts Wet 2006;49:202-4.
Ward S, Lloyd JM, Pandor A, Holmes M, Ara R, Ryan A, et al. A systematic review and economic
evaluation of statins for the prevention of coronary events. Health Technol Assess 2007;11:1-iv.
Waugh JJ, Gupta M, Rushbrook J, Halligan A, Shennan AH. Hidden errors of aneroid
sphygmomanometers. Blood Press Monit 2002;7:309-12.
Wiersma T, Walma EP, Thomas S, Assendelft WJ. Samenvatting van de standaard ‘Hypertensie’
(derde herziening) van het Nederlands Huisartsen Genootschap. Ned Tijdschr Geneeskd
2004;148:923-31.
Wijnhoud AD, Maasland L, Lingsma HF, Steyerberg EW, Koudstaal PJ, Dippel DW. Prediction
of major vascular events in patients with transient ischemic attack or ischemic stroke: a
comparison of 7 models. Stroke 2010;41:2178-85.
Williams PT. Physical fitness and activity as separate heart disease risk factors: a meta-analysis.
Med Sci Sports Exerc 2001;33:754-61.
Williamson DF, Thompson TJ, Thun M, Flanders D, Pamuk E, Byers T. Intentional weight loss
and mortality among overweight individuals with diabetes. Diabetes Care 2000;23:1499-504.
Wolf PA, D’Agostino RB, Kannel WB, Bonita R, Belanger AJ. Cigarette smoking as a risk factor
for stroke. The Framingham Study. JAMA 1988;259:1025-9.
WHO (World Health Organization) Europe. The European health report 2002. Copenhagen:
WHO, 2002.
WHO (World Health Organization). Global Database on Body Mass Index (2011). http://apps.
who.int/bmi/index.jsp?introPage=intro_3.html.
Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensinconverting-enzyme
inhibitor, ramipril, on cardiovascular events in high-risk patients. The
Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145-53.
Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially
modifiable risk factors associated with myocardial infarction in 52 countries (the
INTERHEART study): case-control study. Lancet 2004;364:937-52.
Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, et al. Telmisartan, ramipril, or
both in patients at high risk for vascular events. N Engl J Med 2008;358:1547-59.
Zarnke KB, Feagan BG, Mahon JL, Feldman RD. A randomized study comparing a patientdirected
hypertension management strategy with usual office-based care. Am J Hypertens
1997;10:58-67.
Zipes DP, Wellens HJ. Sudden cardiac death. Circulation 1998;98:2334-51.
MULTIDISCIPLINAIRE RICHTLIJN CARDIOVASCULAIR RISICOMANAGEMENT 136